SynthesisThe American journal of medicine2011
Short-term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia.
Synthesis in The American journal of medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04588207 (Urea for Chronic Hyponatremia), which is not on this map. Cited by 14 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Urea for Chronic Hyponatremia: A Pilot Study
Who cites it
14 citing papers in PubMed, 3 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Interventions for chronic non-hypovolaemic hypotonic hyponatraemia.The Cochrane database of systematic reviews · 2018Pooled it
- Efficacy and Safety of Vasopressin Receptor Antagonists for Euvolemic or Hypervolemic Hyponatremia: A Meta-Analysis.Medicine · 2016Pooled it
- Vasopressin receptor antagonists for the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials.International urology and nephrology · 2015Pooled it
- Efficacy of combination therapy with natriuretic and aquaretic drugs in cirrhotic ascites patients: A randomized study.World journal of gastroenterology · 2017Trial
- [Hyponatremia : Etiology, diagnosis and acute therapy].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2023Article
- Safety and Efficacy of Vaptans in the Treatment of Hyponatremia from Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2023Review
- Prevalence of Admission Hyponatremia in Patients With Diabetes Treated With and Without an SGLT2 inhibitor.Journal of the Endocrine Society · 2023Article
- Hyponatremia in Cirrhosis.Clinics in liver disease · 2022Review
- Early Administration of Tolvaptan Can Improve Survival in Patients with Cirrhotic Ascites.Journal of clinical medicine · 2021Article
- Correction of Hyponatremia May Be a Treatment Stratification Biomarker: A Two-Stage Systematic Review and Meta-Analysis.Journal of clinical medicine · 2018Article
- Efficacy and safety of two different tolvaptan doses in the treatment of hyponatremia in the Emergency Department.Internal and emergency medicine · 2017Article
- Vasopressin Receptor Antagonists in Hyponatremia: Uses and Misuses.Frontiers in medicine · 2017Review
- Tolvaptan for hyponatremia with preserved sodium pool in critically ill patients.Annals of intensive care · 2016Article
- Mild Chronic Hyponatremia in the Ambulatory Setting: Significance and Management.Clinical journal of the American Society of Nephrology : CJASN · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundWe performed a meta-analysis to systematically measure efficacy and safety of vasopressin receptor antagonists (VRAs) tested in randomized controlled trials for treatment of hyponatremia.
methodsMEDLINE, ClinicalTrials.gov, and scientific abstracts were searched without language restriction. Two authors independently screened citations and extracted data on patient characteristics, quality of reports, and efficacy and safety endpoints.
resultsEleven trials were identified (1094 patients). By meta-analysis, VRAs achieved a net increase in serum sodium concentration ([Na(+)](serum)) relative to placebo of 3.3 mEq/L at day 1 (95% confidence interval [CI], 2.7-3.8), and 4.2 mEq/L at day 2 (95% CI, 3.6-4.8), persisting at days 3-5. Larger net increases in [Na(+)](serum) at days 1-4 were observed in euvolemic hyponatremia and with higher doses. VRAs induced a net increase in effective water clearance relative to placebo of 1244 mL at day 1 (95% CI, 920-1567), persisting at days 2 and 4. VRAs were associated with odds ratios of 3.0 for overly rapid correction of [Na(+)](serum) (P <.001), 7.8 for development of hypernatremia (P <.001), 3.3 for thirst development (P <.001), and 2.2 for postural hypotension (P=.04).
conclusionsShort-term use of VRAs in treating hyponatremia was successful at raising [Na(+)](serum). Additional experience is required to guide their optimal use and minimize safety concerns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.